nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosphenytoin—CYP3A4—bone cancer	0.62	1	CbGaD
Fosphenytoin—CYP2B6—Cisplatin—bone cancer	0.0467	0.329	CbGbCtD
Fosphenytoin—CYP2B6—Doxorubicin—bone cancer	0.0313	0.22	CbGbCtD
Fosphenytoin—ALB—Methotrexate—bone cancer	0.0297	0.209	CbGbCtD
Fosphenytoin—CYP2C9—Cisplatin—bone cancer	0.0246	0.174	CbGbCtD
Fosphenytoin—CYP3A4—Doxorubicin—bone cancer	0.0096	0.0677	CbGbCtD
Fosphenytoin—SCN5A—Cardiac Progenitor Differentiation—T—bone cancer	0.00163	0.0907	CbGpPWpGaD
Fosphenytoin—SCN5A—SIDS Susceptibility Pathways—FEV—bone cancer	0.000807	0.045	CbGpPWpGaD
Fosphenytoin—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000767	0.0427	CbGpPWpGaD
Fosphenytoin—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000649	0.0362	CbGpPWpGaD
Fosphenytoin—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.000644	0.0359	CbGpPWpGaD
Fosphenytoin—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00062	0.0346	CbGpPWpGaD
Fosphenytoin—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000579	0.0323	CbGpPWpGaD
Fosphenytoin—Phenylbutazone—CYP3A4—bone cancer	0.000568	0.289	CrCbGaD
Fosphenytoin—Phenylbutazone—PTGS2—bone cancer	0.000556	0.283	CrCbGaD
Fosphenytoin—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000528	0.0294	CbGpPWpGaD
Fosphenytoin—ALB—Folate Metabolism—FOLR1—bone cancer	0.000515	0.0287	CbGpPWpGaD
Fosphenytoin—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000505	0.0281	CbGpPWpGaD
Fosphenytoin—Modafinil—CYP3A4—bone cancer	0.000445	0.227	CrCbGaD
Fosphenytoin—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000414	0.0231	CbGpPWpGaD
Fosphenytoin—Phenytoin—CYP3A4—bone cancer	0.000395	0.201	CrCbGaD
Fosphenytoin—Malaise—Cisplatin—bone cancer	0.000388	0.00178	CcSEcCtD
Fosphenytoin—Leukopenia—Cisplatin—bone cancer	0.000385	0.00177	CcSEcCtD
Fosphenytoin—Anaphylactoid reaction—Epirubicin—bone cancer	0.000379	0.00174	CcSEcCtD
Fosphenytoin—Eye pain—Doxorubicin—bone cancer	0.000376	0.00173	CcSEcCtD
Fosphenytoin—Cardiac failure congestive—Doxorubicin—bone cancer	0.000374	0.00172	CcSEcCtD
Fosphenytoin—Convulsion—Cisplatin—bone cancer	0.000373	0.00171	CcSEcCtD
Fosphenytoin—Mood swings—Methotrexate—bone cancer	0.000371	0.00171	CcSEcCtD
Fosphenytoin—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.00037	0.0206	CbGpPWpGaD
Fosphenytoin—Ataxia—Methotrexate—bone cancer	0.000369	0.00169	CcSEcCtD
Fosphenytoin—Osteoarthritis—Epirubicin—bone cancer	0.000367	0.00168	CcSEcCtD
Fosphenytoin—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000367	0.00168	CcSEcCtD
Fosphenytoin—Diplopia—Epirubicin—bone cancer	0.000367	0.00168	CcSEcCtD
Fosphenytoin—Myalgia—Cisplatin—bone cancer	0.000366	0.00168	CcSEcCtD
Fosphenytoin—Liver function test abnormal—Methotrexate—bone cancer	0.000362	0.00166	CcSEcCtD
Fosphenytoin—Discomfort—Cisplatin—bone cancer	0.000362	0.00166	CcSEcCtD
Fosphenytoin—Affect lability—Epirubicin—bone cancer	0.000361	0.00166	CcSEcCtD
Fosphenytoin—Migraine—Epirubicin—bone cancer	0.000361	0.00166	CcSEcCtD
Fosphenytoin—Face oedema—Epirubicin—bone cancer	0.000354	0.00163	CcSEcCtD
Fosphenytoin—Anaphylactic shock—Cisplatin—bone cancer	0.000351	0.00161	CcSEcCtD
Fosphenytoin—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000351	0.00161	CcSEcCtD
Fosphenytoin—Cardiac arrest—Epirubicin—bone cancer	0.000349	0.0016	CcSEcCtD
Fosphenytoin—Infection—Cisplatin—bone cancer	0.000349	0.0016	CcSEcCtD
Fosphenytoin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000348	0.0194	CbGpPWpGaD
Fosphenytoin—Mood swings—Epirubicin—bone cancer	0.000348	0.0016	CcSEcCtD
Fosphenytoin—Ataxia—Epirubicin—bone cancer	0.000345	0.00158	CcSEcCtD
Fosphenytoin—Thrombocytopenia—Cisplatin—bone cancer	0.000344	0.00158	CcSEcCtD
Fosphenytoin—Tachycardia—Cisplatin—bone cancer	0.000343	0.00157	CcSEcCtD
Fosphenytoin—Dehydration—Epirubicin—bone cancer	0.000341	0.00157	CcSEcCtD
Fosphenytoin—Diplopia—Doxorubicin—bone cancer	0.00034	0.00156	CcSEcCtD
Fosphenytoin—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.00034	0.00156	CcSEcCtD
Fosphenytoin—Osteoarthritis—Doxorubicin—bone cancer	0.00034	0.00156	CcSEcCtD
Fosphenytoin—Hyperhidrosis—Cisplatin—bone cancer	0.00034	0.00156	CcSEcCtD
Fosphenytoin—Asthma—Methotrexate—bone cancer	0.000339	0.00156	CcSEcCtD
Fosphenytoin—Liver function test abnormal—Epirubicin—bone cancer	0.000339	0.00156	CcSEcCtD
Fosphenytoin—Orthostatic hypotension—Epirubicin—bone cancer	0.000335	0.00154	CcSEcCtD
Fosphenytoin—Anorexia—Cisplatin—bone cancer	0.000335	0.00154	CcSEcCtD
Fosphenytoin—Affect lability—Doxorubicin—bone cancer	0.000334	0.00153	CcSEcCtD
Fosphenytoin—Migraine—Doxorubicin—bone cancer	0.000334	0.00153	CcSEcCtD
Fosphenytoin—Hypokalaemia—Epirubicin—bone cancer	0.000334	0.00153	CcSEcCtD
Fosphenytoin—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.00033	0.0184	CbGpPWpGaD
Fosphenytoin—Hypotension—Cisplatin—bone cancer	0.000328	0.00151	CcSEcCtD
Fosphenytoin—Face oedema—Doxorubicin—bone cancer	0.000328	0.0015	CcSEcCtD
Fosphenytoin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000328	0.0183	CbGpPWpGaD
Fosphenytoin—Gastritis—Epirubicin—bone cancer	0.000325	0.00149	CcSEcCtD
Fosphenytoin—Muscular weakness—Epirubicin—bone cancer	0.000324	0.00149	CcSEcCtD
Fosphenytoin—Cardiac arrest—Doxorubicin—bone cancer	0.000323	0.00148	CcSEcCtD
Fosphenytoin—Mood swings—Doxorubicin—bone cancer	0.000322	0.00148	CcSEcCtD
Fosphenytoin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00032	0.00147	CcSEcCtD
Fosphenytoin—Ataxia—Doxorubicin—bone cancer	0.000319	0.00147	CcSEcCtD
Fosphenytoin—Dysphagia—Epirubicin—bone cancer	0.000317	0.00146	CcSEcCtD
Fosphenytoin—Influenza—Epirubicin—bone cancer	0.000317	0.00146	CcSEcCtD
Fosphenytoin—Asthma—Epirubicin—bone cancer	0.000317	0.00146	CcSEcCtD
Fosphenytoin—Dysuria—Methotrexate—bone cancer	0.000317	0.00145	CcSEcCtD
Fosphenytoin—Dehydration—Doxorubicin—bone cancer	0.000316	0.00145	CcSEcCtD
Fosphenytoin—Paraesthesia—Cisplatin—bone cancer	0.000315	0.00145	CcSEcCtD
Fosphenytoin—Liver function test abnormal—Doxorubicin—bone cancer	0.000313	0.00144	CcSEcCtD
Fosphenytoin—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000313	0.0175	CbGpPWpGaD
Fosphenytoin—Dyspnoea—Cisplatin—bone cancer	0.000313	0.00144	CcSEcCtD
Fosphenytoin—Orthostatic hypotension—Doxorubicin—bone cancer	0.00031	0.00142	CcSEcCtD
Fosphenytoin—Photosensitivity reaction—Methotrexate—bone cancer	0.000309	0.00142	CcSEcCtD
Fosphenytoin—Hypokalaemia—Doxorubicin—bone cancer	0.000309	0.00142	CcSEcCtD
Fosphenytoin—Decreased appetite—Cisplatin—bone cancer	0.000305	0.0014	CcSEcCtD
Fosphenytoin—Bronchitis—Epirubicin—bone cancer	0.000305	0.0014	CcSEcCtD
Fosphenytoin—Pneumonia—Methotrexate—bone cancer	0.000304	0.0014	CcSEcCtD
Fosphenytoin—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000301	0.0168	CbGpPWpGaD
Fosphenytoin—Gastritis—Doxorubicin—bone cancer	0.0003	0.00138	CcSEcCtD
Fosphenytoin—Muscular weakness—Doxorubicin—bone cancer	0.000299	0.00137	CcSEcCtD
Fosphenytoin—Renal failure—Methotrexate—bone cancer	0.000297	0.00136	CcSEcCtD
Fosphenytoin—Dysuria—Epirubicin—bone cancer	0.000297	0.00136	CcSEcCtD
Fosphenytoin—Conjunctivitis—Methotrexate—bone cancer	0.000294	0.00135	CcSEcCtD
Fosphenytoin—Influenza—Doxorubicin—bone cancer	0.000293	0.00135	CcSEcCtD
Fosphenytoin—Asthma—Doxorubicin—bone cancer	0.000293	0.00135	CcSEcCtD
Fosphenytoin—Dysphagia—Doxorubicin—bone cancer	0.000293	0.00135	CcSEcCtD
Fosphenytoin—Sweating—Methotrexate—bone cancer	0.00029	0.00133	CcSEcCtD
Fosphenytoin—Photosensitivity reaction—Epirubicin—bone cancer	0.000289	0.00133	CcSEcCtD
Fosphenytoin—Feeling abnormal—Cisplatin—bone cancer	0.000289	0.00133	CcSEcCtD
Fosphenytoin—Hyperglycaemia—Epirubicin—bone cancer	0.000286	0.00131	CcSEcCtD
Fosphenytoin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000285	0.0159	CbGpPWpGaD
Fosphenytoin—Epistaxis—Methotrexate—bone cancer	0.000285	0.00131	CcSEcCtD
Fosphenytoin—Pneumonia—Epirubicin—bone cancer	0.000284	0.00131	CcSEcCtD
Fosphenytoin—Bronchitis—Doxorubicin—bone cancer	0.000282	0.0013	CcSEcCtD
Fosphenytoin—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00028	0.0156	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000279	0.0156	CbGpPWpGaD
Fosphenytoin—Renal failure—Epirubicin—bone cancer	0.000278	0.00128	CcSEcCtD
Fosphenytoin—Body temperature increased—Cisplatin—bone cancer	0.000278	0.00127	CcSEcCtD
Fosphenytoin—Conjunctivitis—Epirubicin—bone cancer	0.000275	0.00126	CcSEcCtD
Fosphenytoin—Dysuria—Doxorubicin—bone cancer	0.000274	0.00126	CcSEcCtD
Fosphenytoin—Sweating—Epirubicin—bone cancer	0.000271	0.00124	CcSEcCtD
Fosphenytoin—Pharyngitis—Methotrexate—bone cancer	0.000269	0.00124	CcSEcCtD
Fosphenytoin—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000269	0.015	CbGpPWpGaD
Fosphenytoin—Photosensitivity reaction—Doxorubicin—bone cancer	0.000268	0.00123	CcSEcCtD
Fosphenytoin—Epistaxis—Epirubicin—bone cancer	0.000267	0.00122	CcSEcCtD
Fosphenytoin—Sinusitis—Epirubicin—bone cancer	0.000265	0.00122	CcSEcCtD
Fosphenytoin—Hyperglycaemia—Doxorubicin—bone cancer	0.000265	0.00122	CcSEcCtD
Fosphenytoin—Pneumonia—Doxorubicin—bone cancer	0.000263	0.00121	CcSEcCtD
Fosphenytoin—Bradycardia—Epirubicin—bone cancer	0.000258	0.00119	CcSEcCtD
Fosphenytoin—Renal failure—Doxorubicin—bone cancer	0.000257	0.00118	CcSEcCtD
Fosphenytoin—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000255	0.0142	CbGpPWpGaD
Fosphenytoin—Rhinitis—Epirubicin—bone cancer	0.000254	0.00117	CcSEcCtD
Fosphenytoin—Conjunctivitis—Doxorubicin—bone cancer	0.000254	0.00117	CcSEcCtD
Fosphenytoin—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000254	0.0142	CbGpPWpGaD
Fosphenytoin—Tinnitus—Methotrexate—bone cancer	0.000253	0.00116	CcSEcCtD
Fosphenytoin—Hypoaesthesia—Epirubicin—bone cancer	0.000253	0.00116	CcSEcCtD
Fosphenytoin—Asthenia—Cisplatin—bone cancer	0.000252	0.00116	CcSEcCtD
Fosphenytoin—Pharyngitis—Epirubicin—bone cancer	0.000252	0.00116	CcSEcCtD
Fosphenytoin—Sweating—Doxorubicin—bone cancer	0.000251	0.00115	CcSEcCtD
Fosphenytoin—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000249	0.0139	CbGpPWpGaD
Fosphenytoin—Epistaxis—Doxorubicin—bone cancer	0.000247	0.00113	CcSEcCtD
Fosphenytoin—Sinusitis—Doxorubicin—bone cancer	0.000245	0.00113	CcSEcCtD
Fosphenytoin—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000245	0.0137	CbGpPWpGaD
Fosphenytoin—Chills—Methotrexate—bone cancer	0.000243	0.00112	CcSEcCtD
Fosphenytoin—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000242	0.0135	CbGpPWpGaD
Fosphenytoin—Diarrhoea—Cisplatin—bone cancer	0.00024	0.0011	CcSEcCtD
Fosphenytoin—Bradycardia—Doxorubicin—bone cancer	0.000239	0.0011	CcSEcCtD
Fosphenytoin—Tinnitus—Epirubicin—bone cancer	0.000237	0.00109	CcSEcCtD
Fosphenytoin—Rhinitis—Doxorubicin—bone cancer	0.000235	0.00108	CcSEcCtD
Fosphenytoin—Hypoaesthesia—Doxorubicin—bone cancer	0.000234	0.00107	CcSEcCtD
Fosphenytoin—Pharyngitis—Doxorubicin—bone cancer	0.000233	0.00107	CcSEcCtD
Fosphenytoin—Dysgeusia—Methotrexate—bone cancer	0.000231	0.00106	CcSEcCtD
Fosphenytoin—Back pain—Methotrexate—bone cancer	0.000228	0.00105	CcSEcCtD
Fosphenytoin—Chills—Epirubicin—bone cancer	0.000228	0.00105	CcSEcCtD
Fosphenytoin—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000227	0.0127	CbGpPWpGaD
Fosphenytoin—Vomiting—Cisplatin—bone cancer	0.000223	0.00103	CcSEcCtD
Fosphenytoin—Rash—Cisplatin—bone cancer	0.000221	0.00102	CcSEcCtD
Fosphenytoin—Dermatitis—Cisplatin—bone cancer	0.000221	0.00102	CcSEcCtD
Fosphenytoin—SCN5A—Cardiac Progenitor Differentiation—KIT—bone cancer	0.000221	0.0123	CbGpPWpGaD
Fosphenytoin—Ill-defined disorder—Methotrexate—bone cancer	0.000219	0.00101	CcSEcCtD
Fosphenytoin—Tinnitus—Doxorubicin—bone cancer	0.000219	0.00101	CcSEcCtD
Fosphenytoin—Anaemia—Methotrexate—bone cancer	0.000218	0.001	CcSEcCtD
Fosphenytoin—Flatulence—Epirubicin—bone cancer	0.000218	0.001	CcSEcCtD
Fosphenytoin—Tension—Epirubicin—bone cancer	0.000217	0.000996	CcSEcCtD
Fosphenytoin—Dysgeusia—Epirubicin—bone cancer	0.000216	0.000994	CcSEcCtD
Fosphenytoin—Nervousness—Epirubicin—bone cancer	0.000215	0.000985	CcSEcCtD
Fosphenytoin—Back pain—Epirubicin—bone cancer	0.000214	0.000981	CcSEcCtD
Fosphenytoin—Malaise—Methotrexate—bone cancer	0.000213	0.000978	CcSEcCtD
Fosphenytoin—Muscle spasms—Epirubicin—bone cancer	0.000212	0.000975	CcSEcCtD
Fosphenytoin—Vertigo—Methotrexate—bone cancer	0.000212	0.000974	CcSEcCtD
Fosphenytoin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000211	0.0118	CbGpPWpGaD
Fosphenytoin—Leukopenia—Methotrexate—bone cancer	0.000211	0.00097	CcSEcCtD
Fosphenytoin—Chills—Doxorubicin—bone cancer	0.000211	0.000968	CcSEcCtD
Fosphenytoin—Nausea—Cisplatin—bone cancer	0.000209	0.000958	CcSEcCtD
Fosphenytoin—Cough—Methotrexate—bone cancer	0.000206	0.000946	CcSEcCtD
Fosphenytoin—Ill-defined disorder—Epirubicin—bone cancer	0.000205	0.000941	CcSEcCtD
Fosphenytoin—Convulsion—Methotrexate—bone cancer	0.000205	0.000939	CcSEcCtD
Fosphenytoin—Anaemia—Epirubicin—bone cancer	0.000204	0.000938	CcSEcCtD
Fosphenytoin—Agitation—Epirubicin—bone cancer	0.000203	0.000932	CcSEcCtD
Fosphenytoin—Flatulence—Doxorubicin—bone cancer	0.000201	0.000925	CcSEcCtD
Fosphenytoin—Arthralgia—Methotrexate—bone cancer	0.000201	0.000923	CcSEcCtD
Fosphenytoin—Myalgia—Methotrexate—bone cancer	0.000201	0.000923	CcSEcCtD
Fosphenytoin—Tension—Doxorubicin—bone cancer	0.000201	0.000921	CcSEcCtD
Fosphenytoin—Dysgeusia—Doxorubicin—bone cancer	0.0002	0.000919	CcSEcCtD
Fosphenytoin—Malaise—Epirubicin—bone cancer	0.000199	0.000915	CcSEcCtD
Fosphenytoin—Discomfort—Methotrexate—bone cancer	0.000199	0.000912	CcSEcCtD
Fosphenytoin—Nervousness—Doxorubicin—bone cancer	0.000199	0.000912	CcSEcCtD
Fosphenytoin—Vertigo—Epirubicin—bone cancer	0.000199	0.000912	CcSEcCtD
Fosphenytoin—Syncope—Epirubicin—bone cancer	0.000198	0.00091	CcSEcCtD
Fosphenytoin—Leukopenia—Epirubicin—bone cancer	0.000198	0.000908	CcSEcCtD
Fosphenytoin—Back pain—Doxorubicin—bone cancer	0.000198	0.000908	CcSEcCtD
Fosphenytoin—Muscle spasms—Doxorubicin—bone cancer	0.000197	0.000903	CcSEcCtD
Fosphenytoin—Palpitations—Epirubicin—bone cancer	0.000195	0.000897	CcSEcCtD
Fosphenytoin—Confusional state—Methotrexate—bone cancer	0.000194	0.000892	CcSEcCtD
Fosphenytoin—Loss of consciousness—Epirubicin—bone cancer	0.000194	0.000892	CcSEcCtD
Fosphenytoin—Cough—Epirubicin—bone cancer	0.000193	0.000885	CcSEcCtD
Fosphenytoin—Anaphylactic shock—Methotrexate—bone cancer	0.000193	0.000885	CcSEcCtD
Fosphenytoin—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000192	0.0107	CbGpPWpGaD
Fosphenytoin—Convulsion—Epirubicin—bone cancer	0.000191	0.000879	CcSEcCtD
Fosphenytoin—Infection—Methotrexate—bone cancer	0.000191	0.000879	CcSEcCtD
Fosphenytoin—Hypertension—Epirubicin—bone cancer	0.000191	0.000876	CcSEcCtD
Fosphenytoin—Ill-defined disorder—Doxorubicin—bone cancer	0.00019	0.000871	CcSEcCtD
Fosphenytoin—Anaemia—Doxorubicin—bone cancer	0.000189	0.000868	CcSEcCtD
Fosphenytoin—Thrombocytopenia—Methotrexate—bone cancer	0.000189	0.000866	CcSEcCtD
Fosphenytoin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000188	0.0105	CbGpPWpGaD
Fosphenytoin—Myalgia—Epirubicin—bone cancer	0.000188	0.000864	CcSEcCtD
Fosphenytoin—Arthralgia—Epirubicin—bone cancer	0.000188	0.000864	CcSEcCtD
Fosphenytoin—Agitation—Doxorubicin—bone cancer	0.000188	0.000863	CcSEcCtD
Fosphenytoin—Hyperhidrosis—Methotrexate—bone cancer	0.000186	0.000855	CcSEcCtD
Fosphenytoin—Discomfort—Epirubicin—bone cancer	0.000186	0.000853	CcSEcCtD
Fosphenytoin—Malaise—Doxorubicin—bone cancer	0.000184	0.000847	CcSEcCtD
Fosphenytoin—Dry mouth—Epirubicin—bone cancer	0.000184	0.000845	CcSEcCtD
Fosphenytoin—Vertigo—Doxorubicin—bone cancer	0.000184	0.000843	CcSEcCtD
Fosphenytoin—Anorexia—Methotrexate—bone cancer	0.000184	0.000843	CcSEcCtD
Fosphenytoin—Syncope—Doxorubicin—bone cancer	0.000183	0.000842	CcSEcCtD
Fosphenytoin—Leukopenia—Doxorubicin—bone cancer	0.000183	0.00084	CcSEcCtD
Fosphenytoin—Confusional state—Epirubicin—bone cancer	0.000182	0.000835	CcSEcCtD
Fosphenytoin—Palpitations—Doxorubicin—bone cancer	0.000181	0.00083	CcSEcCtD
Fosphenytoin—Anaphylactic shock—Epirubicin—bone cancer	0.00018	0.000828	CcSEcCtD
Fosphenytoin—Hypotension—Methotrexate—bone cancer	0.00018	0.000827	CcSEcCtD
Fosphenytoin—Loss of consciousness—Doxorubicin—bone cancer	0.00018	0.000825	CcSEcCtD
Fosphenytoin—Infection—Epirubicin—bone cancer	0.000179	0.000823	CcSEcCtD
Fosphenytoin—Cough—Doxorubicin—bone cancer	0.000178	0.000819	CcSEcCtD
Fosphenytoin—Shock—Epirubicin—bone cancer	0.000177	0.000815	CcSEcCtD
Fosphenytoin—Convulsion—Doxorubicin—bone cancer	0.000177	0.000813	CcSEcCtD
Fosphenytoin—Thrombocytopenia—Epirubicin—bone cancer	0.000177	0.000811	CcSEcCtD
Fosphenytoin—Hypertension—Doxorubicin—bone cancer	0.000177	0.00081	CcSEcCtD
Fosphenytoin—Tachycardia—Epirubicin—bone cancer	0.000176	0.000808	CcSEcCtD
Fosphenytoin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000176	0.000806	CcSEcCtD
Fosphenytoin—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000175	0.00976	CbGpPWpGaD
Fosphenytoin—Hyperhidrosis—Epirubicin—bone cancer	0.000174	0.0008	CcSEcCtD
Fosphenytoin—Insomnia—Methotrexate—bone cancer	0.000174	0.0008	CcSEcCtD
Fosphenytoin—Myalgia—Doxorubicin—bone cancer	0.000174	0.000799	CcSEcCtD
Fosphenytoin—Arthralgia—Doxorubicin—bone cancer	0.000174	0.000799	CcSEcCtD
Fosphenytoin—Paraesthesia—Methotrexate—bone cancer	0.000173	0.000795	CcSEcCtD
Fosphenytoin—Discomfort—Doxorubicin—bone cancer	0.000172	0.00079	CcSEcCtD
Fosphenytoin—Anorexia—Epirubicin—bone cancer	0.000172	0.000789	CcSEcCtD
Fosphenytoin—Dyspnoea—Methotrexate—bone cancer	0.000172	0.000789	CcSEcCtD
Fosphenytoin—Somnolence—Methotrexate—bone cancer	0.000171	0.000787	CcSEcCtD
Fosphenytoin—Dry mouth—Doxorubicin—bone cancer	0.00017	0.000782	CcSEcCtD
Fosphenytoin—Dyspepsia—Methotrexate—bone cancer	0.00017	0.000779	CcSEcCtD
Fosphenytoin—Hypotension—Epirubicin—bone cancer	0.000169	0.000774	CcSEcCtD
Fosphenytoin—Confusional state—Doxorubicin—bone cancer	0.000168	0.000773	CcSEcCtD
Fosphenytoin—Decreased appetite—Methotrexate—bone cancer	0.000168	0.000769	CcSEcCtD
Fosphenytoin—Anaphylactic shock—Doxorubicin—bone cancer	0.000167	0.000766	CcSEcCtD
Fosphenytoin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000167	0.00929	CbGpPWpGaD
Fosphenytoin—Infection—Doxorubicin—bone cancer	0.000166	0.000761	CcSEcCtD
Fosphenytoin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000164	0.000754	CcSEcCtD
Fosphenytoin—Shock—Doxorubicin—bone cancer	0.000164	0.000754	CcSEcCtD
Fosphenytoin—Thrombocytopenia—Doxorubicin—bone cancer	0.000163	0.00075	CcSEcCtD
Fosphenytoin—Insomnia—Epirubicin—bone cancer	0.000163	0.000749	CcSEcCtD
Fosphenytoin—Tachycardia—Doxorubicin—bone cancer	0.000163	0.000748	CcSEcCtD
Fosphenytoin—Paraesthesia—Epirubicin—bone cancer	0.000162	0.000744	CcSEcCtD
Fosphenytoin—Hyperhidrosis—Doxorubicin—bone cancer	0.000161	0.000741	CcSEcCtD
Fosphenytoin—Dyspnoea—Epirubicin—bone cancer	0.000161	0.000738	CcSEcCtD
Fosphenytoin—Somnolence—Epirubicin—bone cancer	0.00016	0.000736	CcSEcCtD
Fosphenytoin—Anorexia—Doxorubicin—bone cancer	0.000159	0.00073	CcSEcCtD
Fosphenytoin—Feeling abnormal—Methotrexate—bone cancer	0.000159	0.000729	CcSEcCtD
Fosphenytoin—Dyspepsia—Epirubicin—bone cancer	0.000159	0.000729	CcSEcCtD
Fosphenytoin—Decreased appetite—Epirubicin—bone cancer	0.000157	0.00072	CcSEcCtD
Fosphenytoin—Hypotension—Doxorubicin—bone cancer	0.000156	0.000716	CcSEcCtD
Fosphenytoin—Constipation—Epirubicin—bone cancer	0.000154	0.000708	CcSEcCtD
Fosphenytoin—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000154	0.00856	CbGpPWpGaD
Fosphenytoin—Urticaria—Methotrexate—bone cancer	0.000153	0.000703	CcSEcCtD
Fosphenytoin—Body temperature increased—Methotrexate—bone cancer	0.000152	0.000699	CcSEcCtD
Fosphenytoin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000152	0.000698	CcSEcCtD
Fosphenytoin—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000152	0.00845	CbGpPWpGaD
Fosphenytoin—Insomnia—Doxorubicin—bone cancer	0.000151	0.000693	CcSEcCtD
Fosphenytoin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00015	0.00836	CbGpPWpGaD
Fosphenytoin—Paraesthesia—Doxorubicin—bone cancer	0.00015	0.000688	CcSEcCtD
Fosphenytoin—Dyspnoea—Doxorubicin—bone cancer	0.000149	0.000683	CcSEcCtD
Fosphenytoin—Feeling abnormal—Epirubicin—bone cancer	0.000149	0.000682	CcSEcCtD
Fosphenytoin—Somnolence—Doxorubicin—bone cancer	0.000148	0.000681	CcSEcCtD
Fosphenytoin—Dyspepsia—Doxorubicin—bone cancer	0.000147	0.000674	CcSEcCtD
Fosphenytoin—Decreased appetite—Doxorubicin—bone cancer	0.000145	0.000666	CcSEcCtD
Fosphenytoin—Urticaria—Epirubicin—bone cancer	0.000143	0.000658	CcSEcCtD
Fosphenytoin—Constipation—Doxorubicin—bone cancer	0.000143	0.000655	CcSEcCtD
Fosphenytoin—Body temperature increased—Epirubicin—bone cancer	0.000143	0.000655	CcSEcCtD
Fosphenytoin—ALB—Folate Metabolism—DHFR—bone cancer	0.000141	0.00788	CbGpPWpGaD
Fosphenytoin—Asthenia—Methotrexate—bone cancer	0.000138	0.000635	CcSEcCtD
Fosphenytoin—Feeling abnormal—Doxorubicin—bone cancer	0.000138	0.000631	CcSEcCtD
Fosphenytoin—Pruritus—Methotrexate—bone cancer	0.000136	0.000626	CcSEcCtD
Fosphenytoin—Urticaria—Doxorubicin—bone cancer	0.000133	0.000609	CcSEcCtD
Fosphenytoin—Body temperature increased—Doxorubicin—bone cancer	0.000132	0.000606	CcSEcCtD
Fosphenytoin—Diarrhoea—Methotrexate—bone cancer	0.000132	0.000605	CcSEcCtD
Fosphenytoin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00013	0.00725	CbGpPWpGaD
Fosphenytoin—Asthenia—Epirubicin—bone cancer	0.000129	0.000594	CcSEcCtD
Fosphenytoin—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000128	0.00715	CbGpPWpGaD
Fosphenytoin—Pruritus—Epirubicin—bone cancer	0.000128	0.000586	CcSEcCtD
Fosphenytoin—Dizziness—Methotrexate—bone cancer	0.000127	0.000585	CcSEcCtD
Fosphenytoin—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000125	0.00694	CbGpPWpGaD
Fosphenytoin—ALB—Platelet degranulation—SPARC—bone cancer	0.000124	0.00691	CbGpPWpGaD
Fosphenytoin—Diarrhoea—Epirubicin—bone cancer	0.000123	0.000567	CcSEcCtD
Fosphenytoin—Vomiting—Methotrexate—bone cancer	0.000123	0.000563	CcSEcCtD
Fosphenytoin—Rash—Methotrexate—bone cancer	0.000122	0.000558	CcSEcCtD
Fosphenytoin—Dermatitis—Methotrexate—bone cancer	0.000121	0.000557	CcSEcCtD
Fosphenytoin—Headache—Methotrexate—bone cancer	0.000121	0.000554	CcSEcCtD
Fosphenytoin—Asthenia—Doxorubicin—bone cancer	0.00012	0.00055	CcSEcCtD
Fosphenytoin—Dizziness—Epirubicin—bone cancer	0.000119	0.000548	CcSEcCtD
Fosphenytoin—Pruritus—Doxorubicin—bone cancer	0.000118	0.000542	CcSEcCtD
Fosphenytoin—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000118	0.00658	CbGpPWpGaD
Fosphenytoin—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000116	0.00647	CbGpPWpGaD
Fosphenytoin—Vomiting—Epirubicin—bone cancer	0.000115	0.000526	CcSEcCtD
Fosphenytoin—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000115	0.00639	CbGpPWpGaD
Fosphenytoin—Nausea—Methotrexate—bone cancer	0.000114	0.000526	CcSEcCtD
Fosphenytoin—Diarrhoea—Doxorubicin—bone cancer	0.000114	0.000524	CcSEcCtD
Fosphenytoin—Rash—Epirubicin—bone cancer	0.000114	0.000522	CcSEcCtD
Fosphenytoin—Dermatitis—Epirubicin—bone cancer	0.000114	0.000522	CcSEcCtD
Fosphenytoin—Headache—Epirubicin—bone cancer	0.000113	0.000519	CcSEcCtD
Fosphenytoin—Dizziness—Doxorubicin—bone cancer	0.00011	0.000507	CcSEcCtD
Fosphenytoin—Nausea—Epirubicin—bone cancer	0.000107	0.000492	CcSEcCtD
Fosphenytoin—Vomiting—Doxorubicin—bone cancer	0.000106	0.000487	CcSEcCtD
Fosphenytoin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000106	0.0059	CbGpPWpGaD
Fosphenytoin—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000105	0.00588	CbGpPWpGaD
Fosphenytoin—Rash—Doxorubicin—bone cancer	0.000105	0.000483	CcSEcCtD
Fosphenytoin—Dermatitis—Doxorubicin—bone cancer	0.000105	0.000483	CcSEcCtD
Fosphenytoin—Headache—Doxorubicin—bone cancer	0.000105	0.00048	CcSEcCtD
Fosphenytoin—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000104	0.00582	CbGpPWpGaD
Fosphenytoin—Nausea—Doxorubicin—bone cancer	9.91e-05	0.000455	CcSEcCtD
Fosphenytoin—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.41e-05	0.00525	CbGpPWpGaD
Fosphenytoin—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.58e-05	0.00478	CbGpPWpGaD
Fosphenytoin—SCN5A—L1CAM interactions—EGFR—bone cancer	7.39e-05	0.00412	CbGpPWpGaD
Fosphenytoin—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	6.67e-05	0.00372	CbGpPWpGaD
Fosphenytoin—CYP2B6—Biological oxidations—CYP3A4—bone cancer	6.62e-05	0.00369	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	6.52e-05	0.00364	CbGpPWpGaD
Fosphenytoin—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	6.38e-05	0.00356	CbGpPWpGaD
Fosphenytoin—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	5.95e-05	0.00332	CbGpPWpGaD
Fosphenytoin—CYP2B6—Biological oxidations—GSTP1—bone cancer	5.66e-05	0.00315	CbGpPWpGaD
Fosphenytoin—CYP2C8—Biological oxidations—CYP3A4—bone cancer	5.6e-05	0.00312	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	5.58e-05	0.00311	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	5.52e-05	0.00308	CbGpPWpGaD
Fosphenytoin—SCN5A—Axon guidance—MET—bone cancer	5.52e-05	0.00307	CbGpPWpGaD
Fosphenytoin—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	5.5e-05	0.00306	CbGpPWpGaD
Fosphenytoin—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.43e-05	0.00302	CbGpPWpGaD
Fosphenytoin—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	5.03e-05	0.0028	CbGpPWpGaD
Fosphenytoin—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5e-05	0.00279	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	4.93e-05	0.00275	CbGpPWpGaD
Fosphenytoin—CYP2C8—Biological oxidations—GSTP1—bone cancer	4.79e-05	0.00267	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	4.72e-05	0.00263	CbGpPWpGaD
Fosphenytoin—SCN5A—Axon guidance—MMP2—bone cancer	4.6e-05	0.00256	CbGpPWpGaD
Fosphenytoin—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.56e-05	0.00254	CbGpPWpGaD
Fosphenytoin—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	4.56e-05	0.00254	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.5e-05	0.00251	CbGpPWpGaD
Fosphenytoin—CYP2C19—Biological oxidations—GSTP1—bone cancer	4.28e-05	0.00238	CbGpPWpGaD
Fosphenytoin—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.27e-05	0.00238	CbGpPWpGaD
Fosphenytoin—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	4.22e-05	0.00235	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.22e-05	0.00235	CbGpPWpGaD
Fosphenytoin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.97e-05	0.00221	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—NDUFA12—bone cancer	3.97e-05	0.00221	CbGpPWpGaD
Fosphenytoin—SCN5A—Developmental Biology—CDK4—bone cancer	3.94e-05	0.00219	CbGpPWpGaD
Fosphenytoin—SCN5A—Developmental Biology—MET—bone cancer	3.94e-05	0.00219	CbGpPWpGaD
Fosphenytoin—CYP2C9—Biological oxidations—GSTP1—bone cancer	3.9e-05	0.00217	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	3.84e-05	0.00214	CbGpPWpGaD
Fosphenytoin—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.69e-05	0.00205	CbGpPWpGaD
Fosphenytoin—SCN5A—Axon guidance—MMP9—bone cancer	3.46e-05	0.00193	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—NDUFA12—bone cancer	3.36e-05	0.00187	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—NDUFA12—bone cancer	3.34e-05	0.00186	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—NT5C3A—bone cancer	3.29e-05	0.00183	CbGpPWpGaD
Fosphenytoin—SCN5A—Developmental Biology—MMP2—bone cancer	3.28e-05	0.00183	CbGpPWpGaD
Fosphenytoin—ALB—Folate Metabolism—TP53—bone cancer	3.16e-05	0.00176	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—NDUFA12—bone cancer	3e-05	0.00167	CbGpPWpGaD
Fosphenytoin—ALB—Hemostasis—SPARC—bone cancer	2.83e-05	0.00158	CbGpPWpGaD
Fosphenytoin—SCN5A—Axon guidance—EGFR—bone cancer	2.79e-05	0.00156	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—NT5C3A—bone cancer	2.78e-05	0.00155	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—NT5C3A—bone cancer	2.77e-05	0.00154	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—NDUFA12—bone cancer	2.73e-05	0.00152	CbGpPWpGaD
Fosphenytoin—ALB—Hemostasis—GNA11—bone cancer	2.59e-05	0.00144	CbGpPWpGaD
Fosphenytoin—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.57e-05	0.00143	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.54e-05	0.00141	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—NT5C3A—bone cancer	2.48e-05	0.00138	CbGpPWpGaD
Fosphenytoin—SCN5A—Developmental Biology—MMP9—bone cancer	2.47e-05	0.00138	CbGpPWpGaD
Fosphenytoin—ALB—Hemostasis—IL3—bone cancer	2.35e-05	0.00131	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—NT5C3A—bone cancer	2.26e-05	0.00126	CbGpPWpGaD
Fosphenytoin—SCN5A—Developmental Biology—EGFR—bone cancer	1.99e-05	0.00111	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—NDUFA12—bone cancer	1.8e-05	0.001	CbGpPWpGaD
Fosphenytoin—ALB—Hemostasis—PLAU—bone cancer	1.54e-05	0.000859	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—NT5C3A—bone cancer	1.49e-05	0.000832	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—ENO2—bone cancer	1.44e-05	0.000802	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—DHFR—bone cancer	1.34e-05	0.000744	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—GNA11—bone cancer	1.25e-05	0.000696	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—ENO2—bone cancer	1.22e-05	0.000679	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—ENO2—bone cancer	1.21e-05	0.000675	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—CYP3A4—bone cancer	1.13e-05	0.000631	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—DHFR—bone cancer	1.13e-05	0.00063	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—DHFR—bone cancer	1.12e-05	0.000627	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—ENO2—bone cancer	1.09e-05	0.000606	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—GNA11—bone cancer	1.06e-05	0.000589	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—GNA11—bone cancer	1.05e-05	0.000586	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—DHFR—bone cancer	1.01e-05	0.000562	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—ENO2—bone cancer	9.92e-06	0.000553	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—GSTP1—bone cancer	9.68e-06	0.000539	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—CYP3A4—bone cancer	9.58e-06	0.000534	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.53e-06	0.000531	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—CYP3A4—bone cancer	9.52e-06	0.000531	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.47e-06	0.000528	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—GNA11—bone cancer	9.43e-06	0.000526	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—DHFR—bone cancer	9.2e-06	0.000513	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—GNA11—bone cancer	8.6e-06	0.000479	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—CYP3A4—bone cancer	8.55e-06	0.000477	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.51e-06	0.000474	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—GSTP1—bone cancer	8.19e-06	0.000457	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—GSTP1—bone cancer	8.14e-06	0.000454	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—CYP3A4—bone cancer	7.79e-06	0.000435	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.76e-06	0.000432	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—GSTP1—bone cancer	7.31e-06	0.000408	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—GSTP1—bone cancer	6.67e-06	0.000372	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—ENO2—bone cancer	6.54e-06	0.000365	CbGpPWpGaD
Fosphenytoin—ALB—Hemostasis—TP53—bone cancer	6.19e-06	0.000345	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—DHFR—bone cancer	6.07e-06	0.000338	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—GNA11—bone cancer	5.67e-06	0.000316	CbGpPWpGaD
Fosphenytoin—CYP2B6—Metabolism—PTGS2—bone cancer	5.01e-06	0.000279	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—GSTP1—bone cancer	4.4e-06	0.000245	CbGpPWpGaD
Fosphenytoin—CYP2C8—Metabolism—PTGS2—bone cancer	4.24e-06	0.000237	CbGpPWpGaD
Fosphenytoin—ALB—Metabolism—PTGS2—bone cancer	4.22e-06	0.000235	CbGpPWpGaD
Fosphenytoin—CYP2C19—Metabolism—PTGS2—bone cancer	3.79e-06	0.000211	CbGpPWpGaD
Fosphenytoin—CYP2C9—Metabolism—PTGS2—bone cancer	3.45e-06	0.000193	CbGpPWpGaD
Fosphenytoin—CYP3A4—Metabolism—PTGS2—bone cancer	2.28e-06	0.000127	CbGpPWpGaD
